tbuckley/cabot-search huggingface dataset:
PTU-007 Comparison of Diagnostic Performance Between Two Core Biopsy Needles for Endoscopic Ultrasound-Guided Tissue Acquisition of Solid Pancreatic Lesions
Authors: B Paranandi, KW Oppong, M Dawwas, JS Leeds, A Darne, B Haugk, D Majumdar, MM Ahmed, MK Nayar
Journal: Gut (2016)

<h3>Introduction</h3> A new core biopsy needle (SharkCore) with a novel design has recently been introduced for endoscopic ultrasound guided biopsy. There is as yet no data on how its diagnostic performance compares to the existing core biopsy needle (Procore) in the diagnosis of pancreatic masses. The aim of this study was to compare the diagnostic performance and yield of the two core biopsy needles i.e. the ProCore and the Sharkcore needles in the biopsy of solid pancreatic lesions. This is the first study in literature to compare 2 core biopsy needles. <h3>Methods</h3> A retrospective comparison of a prospectively maintained database. Consecutive patients who had EUS guided fine needle biopsy with Procore (100) and Sharkcore (101) were included in the study. Demographic details, site of lesion, number of passes and histological diagnosis. Final diagnosis was based on positive histology or at least 6 months follow up in cases with a benign pathology. Primary outcome was to compare the diagnostic accuracy of the two needles using only samples graded as definitely malignant as diagnostic for malignancy. The secondary outcome was to compare the diagnostic yield for both needles. <h3>Results</h3> The sensitivity, specificity, negative predictive value and accuracy between the groups were - Procore =71%, 100%, 28% and 74% vs. Sharkcore =91%, 100%, 53% and 94%. There was a significant difference in sensitivity (p = 0.0003) and accuracy (p = 0.006). The proportion of samples classified as adequate for histological analysis was 87% for Procore and 99% for Sharkcore - this was significantly different (p = 0.0009). There were no complications in either group. <h3>Conclusion</h3> In this study the SharkCore biopsy needle demonstrated significantly better diagnostic accuracy and tissue yield. Prospective randomised studies are required. <h3>Disclosure of Interest</h3> None Declared
18F-NaF PET Demonstrating Unusual Focal Tracer Activity in the Brain
Authors: Anuradha Thenkondar, Lida Jafari, Robbie Sooriash, Fereshteh Hajsadeghi, Gholam R. Berenji, Yuxin Li
Journal: Clinical Nuclear Medicine (2016)

A 60-year-old man with enlarged prostate, hypertension, and diabetes was referred for F-NaF PET/CT to evaluate possible metastatic lesions. The patient appeared asymptomatic on the day of the study, without any signs indicating stroke. Patient also had no known history of malignancy or cerebrovascular disease. He had mild elevation of the prostate-specific antigen level, and biopsy of his prostate was not performed. Patient had long-standing history of chronic back pain and abdominal pain. The PET bone scan demonstrated a large area of very intense tracer uptake in the brain. A subsequent brain MRI revealed prior stroke in the same area.
Sponge on string could replace endoscopy in patients with Barrett’s oesophagus
Authors: Zosia Kmietowicz
Journal: BMJ (2016)

A pill that expands into a sponge when swallowed could be used by GPs to identify which people with Barrett’s oesophagus have a low risk of developing oesophageal cancer and could avoid the need for endoscopies, researchers at Cancer Research UK have found.1

Determining which patients with Barrett’s oesophagus, which can lead to oesophageal cancer in a small number of people, have a low risk of developing cancer could help to reduce overdiagnosis and overtreatment in this group, said the researchers.

About one in …
Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial
Authors: Clive S. Zent, Betsy R. LaPlant, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Wei Ding, George J. Weiner, Thomas E. Witzig
Journal: Blood (2012)
Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals
Authors: Li Liu, Shefali Oza, Dan Hogan, Yue Chu, Jamie Perin, Jun Zhu, Joy E Lawn, Simon Cousens, Colin Mathers, Robert E Black
Journal: The Lancet (2016)

BackgroundDespite remarkable progress in the improvement of child survival between 1990 and 2015, the Millennium Development Goal (MDG) 4 target of a two-thirds reduction of under-5 mortality rate (U5MR) was not achieved globally. In this paper, we updated our annual estimates of child mortality by cause to 2000–15 to reflect on progress toward the MDG 4 and consider implications for the Sustainable Development Goals (SDG) target for child survival.MethodsWe increased the estimation input data for causes of deaths by 43% among neonates and 23% among 1–59-month-olds, respectively. We used adequate vital registration (VR) data where available, and modelled cause-specific mortality fractions applying multinomial logistic regressions using adequate VR for low U5MR countries and verbal autopsy data for high U5MR countries. We updated the estimation to use Plasmodium falciparum parasite rate in place of malaria index in the modelling of malaria deaths; to use adjusted empirical estimates instead of modelled estimates for China; and to consider the effects of pneumococcal conjugate vaccine and rotavirus vaccine in the estimation.FindingsIn 2015, among the 5·9 million under-5 deaths, 2·7 million occurred in the neonatal period. The leading under-5 causes were preterm birth complications (1·055 million [95% uncertainty range (UR) 0·935–1·179]), pneumonia (0·921 million [0·812 −1·117]), and intrapartum-related events (0·691 million [0·598 −0·778]). In the two MDG regions with the most under-5 deaths, the leading cause was pneumonia in sub-Saharan Africa and preterm birth complications in southern Asia. Reductions in mortality rates for pneumonia, diarrhoea, neonatal intrapartum-related events, malaria, and measles were responsible for 61% of the total reduction of 35 per 1000 livebirths in U5MR in 2000–15. Stratified by U5MR, pneumonia was the leading cause in countries with very high U5MR. Preterm birth complications and pneumonia were both important in high, medium high, and medium child mortality countries; whereas congenital abnormalities was the most important cause in countries with low and very low U5MR.InterpretationIn the SDG era, countries are advised to prioritise child survival policy and programmes based on their child cause-of-death composition. Continued and enhanced efforts to scale up proven life-saving interventions are needed to achieve the SDG child survival target.FundingBill & Melinda Gates Foundation, WHO.
AB0492 Mortality in Systemic Lupus Erythematosus: Causes and Risk Factors in A Group of Tunisian Patients
Authors: T. Ben Salem, M. Tougorti, I. Naceur, M. Lamloum, M. Khanfir, I. Ben Ghorbel, M.H. Houman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Mortality risk in patients with (SLE) is higher than in general population. The aim of this study was to determine mortality causes in a group of SLE patients. <h3>Methods</h3> A retrospective study of patients who fulfilled the revised ACR criteria of SLE and admitted in an Internal Medicine department from 2000 to 2013. Data were recorded and analyzed for clinical, biological manifestations, infections and complications. Mortality causes were noted. <h3>Results</h3> Twenty three patients out of 246 SLE patients died (9.3%). They were 22 female and 1 male. Mean age at disease onset 33.5±16.1 years. During SLE course, patients presented with arthralgia (n=21), pericardial effusion (n=15), lupus nephritis (n=14), pleural effusion (n=9), hepatitis (n=7), neurologic manifestations (n=6) and pulmonary hypertension (n=2). Patients were given corticosteroid in 95.6% of cases and immunosuppressive drugs in 60.8% of cases. Immunosuppressive treatment were based on cyclophosphamide (n=10), azathioprine (n=7), mycophenolate Mofetil (n=2) and cyclosporine (n=1). SLE was in remission in 82.6% of cases when death occurred and four patients were in relapse without other conditions. Death was related to infections in 13 cases: pneumonia (n=5), urinary tract infection (n=4), skin infection (n=2), tuberculosis (n=1) and pulmonary aspergillosis (n=1). Three patients had cancer (one lung cancer, one cecum cancer and one still indeterminate). Death occurred in two patients because of heart failure and was related to a severe pulmonary hypertension. Pericarditis (65.2% vs 36.9%; p=0.01), anti-histone antibodies (83.3% vs 49%; p=0.031) and infections (91.3% vs 60.1%; p=0.004) were statistically more frequent in dead patients. Lupus nephritis was also more frequent in these patients (63.6% vs 43%; p=0.068). <h3>Conclusions</h3> Pericarditis and lupus nephritis were a poor factor prognosis in our series. Infection was the main cause of mortality in our patients. In addition to immunosuppression, poor socioeconomic status and lack of health care access in some patients can explain this high prevalence. <h3>Disclosure of Interest</h3> None declared
Therapy for Cellulitis
Authors: Loren G. Miller
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0366 Association of Chromosome 1Q32 with Ankylosing Spondylitis Is Independent of Bowel Symptoms and Faecal Calprotectin
Authors: R.L. Roberts, M. Wallace, A. Harrison, D. White, N. Dalbeth, L. Stamp, D. Ching, J. Highton, T. Merriman, P. Robinson, M. Brown, S. Stebbings
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Colonoscopic, endoscopic, and histological studies have demonstrated that intestinal inflammation, similar to the ileo-colitis seen in Crohn9s disease (CD), is a common feature of ankylosing spondylitis (AS). More recently, the existence of a shared genetic basis to CD and AS has been demonstrated [1,2]. <h3>Objectives</h3> To test whether the association of known CD risk loci with AS is primarily due to the presence of bowel inflammation in AS patients. <h3>Methods</h3> 286 Caucasian patients fulfilling the modified New York criteria for AS and with no history of inflammatory bowel disease were assessed non-invasively for bowel inflammation using faecal calprotectin and the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) [3]. All patients and 568 matched healthy controls were genotyped with TaqMan® SNP genotyping assays for the confirmed CD risk loci [2], 1q32 (rs11584383),<i>JAK2</i> (rs10758669), <i>CDKAL1</i> (rs6908425), <i>IL12B</i> (rs100454310), <i>ZPBP2</i> (rs2872507), <i>MUC19/LRRK2</i> (rs11175593), <i>STAT3</i> (rs744166), and <i>IL23R</i> (rs1343151, rs10489630, rs11209026). Chi square testing was used to test for association. <h3>Results</h3> Minor alleles of 1q32 SNP rs11584383 (p=0.002, OR=0.69, 95% CI 0.55–0.87), and <i>IL23R</i> SNPs rs11209026 (p=0.011, OR=0.53, 95% CI 0.32–0.87) and rs1343151 (p=0.027, OR=0.77, 95% CI 0.61–0.97) all conferred protection against AS. However, only the association of 1q32 SNP rs11584383 remained significant after Bonferroni correction for multiple testing (p=0.02). The Cochran9s Q test found no significant difference between ORs after stratification of AS patients by DISQ score and faecal calprotectin (P<sub>difference</sub> &gt;0.09). <h3>Conclusions</h3> Previously, the association of CD risk loci with susceptibility to AS has been attributed to the co-occurrence of asymptomatic intestinal inflammation which is well recognised and supports the concept that CD and AS are two extremes of a related genetic and phenotypic disease spectrum. However, our study provides preliminary evidence that the association of the confirmed CD risk locus 1q32 SNP rs11584383 with AS is independent of bowel inflammation. <h3>References</h3> Parkes M, et al. 2013. Nature reviews Genetics. 14(9):661–673. Danoy P et al. 2010. PLoS genetics. 6(12):e1001195. Stebbings S et al. 2012. Rheumatology. 51(5):858–865. <h3>Disclosure of Interest</h3> None declared
THU0365 Light rs1077667 G&gt;A Gene Polymorphism Is Associated with Susceptibility To Ankylosing Spondylitis in A Chinese Han Population
Authors: B. Yang, L. Wang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Single-nucleotide polymorphisms (SNPs) are single base-pair changes which will lead to the structural changes of mRNA and get involved in the pathogenesis process of ankylosing spondylitis (AS). LIGHT is indicated to be a inflammatory mediator in AS. Meanwhile the SNP rs1077667 G&gt;A, which was located on LIGHT, is associated with the expression of LIGHT. <h3>Objectives</h3> This study explored the relationship between AS and the SNP rs1077667 G&gt;A in a Han Chinese population. Meanwhile we explored the relationship between the SNP and the laboratory characteristic of AS patients. <h3>Methods</h3> A case-control study with 497 subjects diagnosed AS and 387 healthy controls to compare their genotype and gene frequencies was delivered. SNP is identified by high-resolution melting methods (HRM). Clinical characteristics of patients with AS and controls were registered at the same time. <h3>Results</h3> Statistical significance was found in both co-dominant model (GG vs. GA vs. AA) (P=0.000004) and allele [p=4.59E-08, OR (95%CI) = 0.740 (0.663–0.827)] between LIGHT rs1077667 G&gt;A and the risk of AS. However, no significant association was found between the SNP and the laboratory indexes. <h3>Conclusions</h3> This is the first study to address the association between the LIGHT rs1077667 G&gt;A polymorphisms and AS, and it suggests a potential pathogenic factor for AS. <h3>References</h3> Smith JA (2015) Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 15: 489 Hreggvidsdottir HS, Noordenbos T, Baeten DL (2014) Inflammatory pathways in spondyloarthritis. Mol Immunol 57: 28–37. Wen W, Kato N, Hwang JY, Guo X, Tabara Y, et al. (2016) Genome-wide association studies in East Asians identify new loci for waist-hip ratio and waist circumference. Sci Rep 6: 17958. <h3>Acknowledgement</h3> We are grateful to the participating AS patients and their families. This research was sponsored by the National Natural Science Foundation of China (Nos. 81301496, and 81202354). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. <h3>Disclosure of Interest</h3> B. Yang Shareholder of: No, Grant/research support from: No, Consultant for: No, Employee of: No, Paid instructor for: No, Speakers bureau: No, L. Wang: None declared
MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte
Authors: Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Danielle Canioni, Marie Parrens, Bettina Fabiani, Richard Delarue, Tony Petrella, Gilles Salles, Karim Belhadj, Christian Recher, Nicolas Ketterer, Olivier Fitoussi, Frederic Peyrade, Corinne Haioun, Fabrice Jardin, Karen Leroy, Jean-Philippe Jais, Herve Tilly, Philippe Gaulard, Thierry Jo Molina
Journal: Blood (2012)
Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study
Authors: Valentin Goede, Anja Engelke, Kirsten Fischer, Javier Lopez Jimenez, Alexej Kuzmin, Martin JS Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, Günter Fingerle-Rowson, Michael Hallek
Journal: Blood (2014)
The Hematopoietic Activity of the Homeobox Gene HOXB4 Depends on a N-Terminal Proline-Rich Region In Vitro and In Vivo.
Authors: Monica Cusan, Aniruddha Deshpande, Wolfgang Hiddemann, R. Keith Humphries, Christian Buske, Michaela Feuring-Buske
Journal: Blood (2006)
Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases
Authors: Amandine Le Bourgeois, Florent Malard, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Pierre Peterlin, Patricia Lemarchand, Patrick Germaud, Mohamad Mohty, Philippe Moreau, Arnaud Chambellan
Journal: Blood (2015)
Ultrasonographic findings can identify ‘pseudoprogression’ under nivolumab therapy
Authors: K. Imafuku, H. Hata, S. Kitamura, T. Yanagi, H. Shimizu
Journal: British Journal of Dermatology (2016)

'Pseudoprogression' is often seen in patients with melanomas who are treated with immune checkpoint inhibitors such as nivolumab or ipilimumab. We sometimes evaluate metastatic lesions by imaging tests such as computed tomography (CT) or positron emission tomography-CT. 'Pseudoprogression' usually occurs upon the initial administration, which may make it difficult for the physician to determine the disease condition. In our two cases of metastatic melanoma treated with nivolumab (antiprogrammed cell death-1 antibody), we examined the ultrasonography (US) of target lesions that could be accessed from the body surface, such as those of the regional lymph node or subcutaneous metastasis. In both cases, the US revealed a lesion approximately 10% greater in size after 40-50 days of nivolumab administration, even though the blood flow inside the tumour was reduced by about 20% within 50 days. From about 100 days after blood flow reduction was detected by US, the tumours began to decrease in size. However, contrast CT was unable to detect the association between tumour size and tumour blood flow. The present cases suggest that US could be a powerful tool for differentiating between 'pseudoprogression' and real progressive disease in patients treated with cancer immunotherapies such as those involving immune checkpoint inhibitors. The misdiagnosis of progressive disease can lead to unnecessary alterations to the current treatment. Therefore, the US findings in our study could be clinically useful and educational for physicians.
AB0836 Impact of Epidemioclinical Patients Characteristics on Germ Identification during Septic Arthritis
Authors: H. Sahli Ep Hedi, R. Khalfallah, R. Tekaya, I. Mahmoud, O. Saidane, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Septic arthritis may cause damage and inflammation in short period of time. The germ determination must be the first objective to allow targeted treatment. Bacteriological tests remain negative in 7–35% of cases of septic arthritis. <h3>Objectives</h3> Our objective is to determine the impact of epidemioclinical patients profile on germ determination during septic arthritis. <h3>Methods</h3> This a retrospective study which included medical records of patients treated for septic arthritis during the seventeen past years. Epidemiologic, clinical, biologic, bacteriologic and therapeutic data were recorded and analysed. We made a comparison between patients who had a germ identified with whom who hadn9t. <h3>Results</h3> Fifty nine cases of septic arthritis were treated during the study period with mean age about 54.6±19 years [range 15 to 95]. The germ was identified in 27 cases (45.77%). The patients with no identified microorganism had a female predominance (sex-ratio M/F=0.77). When germ was identified, there was no sex predominance (sex ratio =1.07) with no differences between the 2 groups (p=0.385). The two groups had same mean age (54.1 and 54.8 years). The maximum of frequency of the disease was for patients aged between 70 and 79 years when germ identified and between 40 and 59 years if not. The percentage of patients with risk factors of septic arthritis was higher if the germ was not identified but with no significant difference (p=0.893). Anorexia, weight loss and lameness were more frequently seen if germ wasn9t identified. It was the same ascertainment with fever and inflammatory signs. There was no significant difference between the two groups as regards the arthritis localization and the number of joints involved. <h3>Conclusions</h3> This study showed that female sex was the only epidemio-clinical character associated with low chance to identify the germ during septic arthritis. <h3>Disclosure of Interest</h3> None declared